Keratoacanthoma - Keratoakantom
☆ Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
Tipik Keratoakantom (Keratoacanthoma)
References
Keratoacanthoma (KA) se yon timè po souvan li te ye pou kwasans rapid li ak potansyèl pou l regrese poukont li. Li anjeneral rive nan gason ki pi gran, ki gen po ki jis ki gen yon istwa nan domaj solèy la. Pandan ke retire chirijikal lè l sèvi avèk excision oswa operasyon mikwografik Mohs se tretman nòmal la, gen plizyè lòt opsyon terapi ki disponib.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) se yon timè ki ba-klas ki kòmanse nan sèten glann nan po a epi ki sanble ak squamous cell carcinoma (SCC) anba yon mikwoskòp. Gen deba kontinyèl sou si wi ou non KA ta dwe klase kòm yon fòm SCC anvayisan.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) se dezyèm kalite kansè ki pi komen nan moun, sitou pami moun ki pi gran yo. Operasyon anjeneral itilize pou trete cSCC, men pou kèk pasyan ki pa ka fè operasyon oswa ki chwazi pa fè sa, yo ka konsidere lòt opsyon tankou tretman entralesional. Yo te itilize tretman tradisyonèl intralesional (methotrexate or 5-fluorouracil) , men gen rechèch k ap kontinye sou nouvo apwòch tankou imunoterapi entralesional ak viroterapi onkolitik. Isit la, nou pral gade diferan tretman entralesional pou cSCC, sòti nan metòd klasik ak estrateji dènye kri.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Anba mikwoskòp la, keratoakantom (keratoacanthoma) sanble anpil ak karsinom selil squamous. Pandan ke kèk patolojis klasifye keratoakantom (keratoacanthoma) kòm yon antite diferan epi yo pa yon maliyans, apeprè 6% nan klinik ak istolojik keratoakantom (keratoacanthoma) fè pwogrè nan kansè selil squamous anvayisan ak agresif.
○ Dyagnostik ak Tretman
#Dermoscopy
#Skin biopsy